BioDlink's Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion
BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil (a PIC/S member), Colombia, Egypt, Indonesia, and...
BioDlink Strengthens Global Compliance with Argentina GMP Certification
Global Milestone: GMP certification from Argentina, marking a key step in its global expansion and regulatory recognition. Scalable, Trustworthy Solutions: With advanced manufacturing capabilities, BioDlink deliver Pusintin® (bevacizumab) injection...
BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth
International recognition of quality system with GMP-compliance in the key markets of Brazil, Indonesia, Egypt, Colombia and Argentina Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory...
BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation...